Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (CKD) Stages 2-4 and elevated urinary albumin excretion. The results were consistent in patients both with and without type-2 diabetes (T2D).

source https://www.pharmatutor.org/pharma-news/2020/farxiga-demonstrated-unprecedented-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease-in-the-phase-iii-dapa-ckd-trial